According to Securities Times APP, on November 6th, at the 7th China International Import Expo (referred to as the Import Expo), Roche Diagnostics Products (Shanghai) Co., Ltd. (referred to as Roche Diagnostics) and Kangsheng Global (Wuhan) Medical Special Inspection Technology Co., Ltd. (referred to as Kangsheng Global) have agreed to cooperate on the construction of a standardized system for the precise diagnosis and treatment of lymphoma in China, and have signed a memorandum of cooperation.

Signing ceremony of the memorandum of cooperation (front row: Chai Haijie, Chief Financial Officer of Kangsheng Global, Huang Beibei, Director of Sales of Roche Diagnostics China Life Sciences Department; back row: Huang Shiang, Founder and CEO of Kangsheng Global, Wang Feng, Senior Director of Roche Diagnostics China).

In recent years, the market for precise diagnosis and treatment of lymphoma has made significant progress. With the rapid development of medical technology and a deeper understanding of disease mechanisms, traditional chemotherapy is gradually being replaced by precise targeted and immunotherapy. The demand for precise diagnostic technologies, especially improvements in pathological diagnosis and molecular testing, has made the diagnosis of lymphoma more accurate. The 5th edition of the World Health Organization (WHO) Blood Lymphoid Tumor Classification released in 2022 requires pathological diagnosis to rely on NGS (second-generation sequencing technology) or other new molecular indicators, highlighting the importance of precise diagnosis.

In the process of constructing the standardized system for the precise diagnosis and treatment of lymphoma in China, Kangsheng Global, leveraging its advantages in the development of molecular diagnostic products for lymphatic system diseases over the years, has completed testing of over 0.02 million clinical samples. The mutation spectrum of the testing is consistent with databases and literature, receiving consistent praise from clinicians.

Recently, Kangsheng Global, along with Roche Diagnostics and Roche Pharmaceuticals, will jointly build an integrated ecosystem for lymphoma diagnosis and treatment, aiming to improve the standardization, precision, and accessibility of lymphoma diagnosis, thereby increasing the cure rate of lymphoma patients. All parties will fully utilize each other's resources and strengths to explore and conduct possible clinical research or scientific cooperation in the field of lymphoma, especially in the construction of "detection standard system," "expert consensus," and "clinical value" in the lymphoma diagnosis and treatment process.

Professor Huang Shiang, Founder and CEO of Kangsheng Global, stated: "Accurate diagnosis is not only the prerequisite for developing effective treatment plans, but also the key to monitoring changes in the condition and evaluating treatment effects. Only by ensuring the advancement, universality, and standardization of diagnostic solutions can more patients benefit. Kangsheng Global has long been committed to the diagnosis and monitoring of blood diseases, providing professional blood special inspection services. We are very pleased to establish a partnership with Roche Diagnostics to jointly promote the standardization and systematization of NGS, contributing more effort to improve the level of diagnosis and treatment of blood diseases."

Mr. Yao Guoliang, General Manager of Roche Diagnostics China, said: "Attending the import expo seven times, we are taking advantage of the ongoing expansion of the local ecosystem through the continuous growth 'import expo momentum', practicing Roche Diagnostics' firm commitment of 'In China, For China' with an open and cooperative spirit, jointly building an integrated diagnosis and treatment system. In the future, we will continue to innovate and look forward to working with industry peers to continuously enhance the accessibility and efficient application of high medical value, high-quality diagnosis and treatment solutions, accelerate the transformation of research results into practical applications, break through the diagnosis and treatment bottleneck of blood diseases, realize the ideal vision of complete cure, and bring good news to more Chinese patients."